Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
British Journal of Haematology
|
September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S Topp, Tom van Meerten, Roch Houot, et al.
Blood
|
May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Vicki Plaks, John M Rossi, Justin Chou, et al.
Nature Medicine
|
August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Cancer Research
|
June 12, 2019
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
Joseph Castillo, Esther Wu, Christopher Lowe, et al.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Blood Cancer Journal
|
November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4
Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
Blood Advances
|
November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression
Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
The Lancet. Oncology
|
January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
British Journal of Haematology
|
September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S Topp, Tom van Meerten, Roch Houot, et al.
Blood
|
May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Vicki Plaks, John M Rossi, Justin Chou, et al.
Nature Medicine
|
August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Cancer Research
|
June 12, 2019
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
Joseph Castillo, Esther Wu, Christopher Lowe, et al.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Blood Cancer Journal
|
November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4
Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
Blood Advances
|
November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression
Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
The Lancet. Oncology
|
January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Page
of 5